The DOI matches its Crossref record.
Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours
Abstract
Chromogranins and/or secretogranins constitute a family of water-soluble acidic glycoproteins that are present in almost all endocrine, neuroendocrine and neuronal tissue. Antibodies against chromogranins have been widely used for immunohistochemical staining of endocrine tissue and tumours of neuroendocrine origin. Furthermore, measurements of circulating chromogranin A have been used as a reliable marker for neuroendocrine tumour growth. In this study, we describe the development of specific antibodies against chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin. The antibodies were used for immunohistochemical staining of normal and neoplastic neuroendocrine tissue and development of reliable radioimmunoassays for chromogranin A, chromogranin B, chromogranin C and pancreastatin. In 44 patients with carcinoid tumours, 17 patients with sporadic endocrine pancreatic tumours and 11 patients with endocrine pancreatic tumours and the multiple endocrine neoplasia 1 syndrome, plasma measurements revealed elevated chromogranin A levels in 99%, elevated chromogranin B in 88%, elevated chromogranin C in 6% and elevated pancreastatin in 46% of the patients. Urinary measurements revealed elevated levels in 39%, 15%, 14% and 33% of the patients respectively. Gel permeation chromatography of plasma and urine showed that circulating chromogranin A, and immunoreactive fragments of chromogranin A, had a higher molecular weight distribution than the chromogranin A fragments excreted to the urine. Furthermore, it was noted that most of the patients excreting chromogranin A fragments to the urine had previously been treated with streptozotocin, a cytotoxic agent known to induce renal tubular dysfunction. The antibodies raised proved useful for immunohistochemical staining and visualised endocrine cells in pancreatic islets, adrenal medulla and the small intestine as well as in endocrine pancreatic tumours, pheochromocytoma and midgut carcinoid tumours. In conclusion, the antibodies raised were useful for both immunohistochemical staining of normal tissue and endocrine tumours as well as development of specific radioimmunoassays for plasma measurements of the different chromogranins. Furthermore, we show that plasma measurements of chromogranin A and B were superior to measurements of chromogranin C and pancreastatin and plasma measurements of the different chromogranins were more reliable as markers for tumour growth than the corresponding urine measurements. Journal of Endocrinology (1995) 144, 49–59
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Current Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
The Chromogranin–Secretogranin Family
Taupenot, L., Harper, K. L., & O'Connor, D. T. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021405 · Cited by 819
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Tumor Markers in Neuroendocrine Tumors
Eriksson, B., Öberg, K., & Stridsberg, M. (2000) · Digestion · doi:10.1159/000051853 · Cited by 299
Self-citationBajetta, E., Ferrari, L., Martinetti, A., Celio, L., Procopio, G., Artale, S., Zilembo, N., Di Bartolomeo, M., Seregni, E., & Bombardieri, E. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990901)86:5<858::aid-cncr23>3.0.co;2-8 · Cited by 289
Consensus on biomarkers for neuroendocrine tumour disease
Oberg, K., Modlin, I. M., De Herder, W., Pavel, M., Klimstra, D., Frilling, A., Metz, D. C., Heaney, A., Kwekkeboom, D., Strosberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00186-2 · Cited by 283
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
O’Toole, D., Grossman, A., Gross, D., Delle Fave, G., Barkmanova, J., O’Connor, J., Pape, U.-F., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225948 · Cited by 268
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177
Chromogranin A: its clinical value as marker of neuroendocrine tumours.
Nobels, Kwekkeboom, Bouillon, & Lamberts (1998) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1998.00305.x · Cited by 151
Sanduleanu, S., De Bruïne, A., Stridsberg, M., Jonkers, D., Biemond, I., Hameeteman, W., Lundqvist, G., & Stockbrügger, R. W. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00890.x · Cited by 114
Self-citationSanduleanu, Stridsberg, Jonkers, Hameeteman, Biemond, Lundqvist, Lamers, & Stockbrügger (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00466.x · Cited by 111
Korse, C. M., Bonfrer, J. M. G., Aaronson, N. K., Hart, A. A. M., & Taal, B. G. (2009) · Neuroendocrinology · doi:10.1159/000162876 · Cited by 61
“reported that the sensitivity of CgA in patients with NET was much higher compared to 5-HIAA (68 and 35p, respectively), while the specificity in patients who were considered disease free was high for both assays (86 and 100p, respectively). We adjusted the CgA assay by diluting the samples to achieve a lower detectio…”
MethodArdill, J. E. S., & O’Dorisio, T. M. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.09.001 · Cited by 49
Børglum, T., Rehfeld, J. F., Drivsholm, L. B., & Hilsted, L. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.076158 · Cited by 42
Library of Sequence-specific Radioimmunoassays for Human Chromogranin A
Børglum Jensen, T., Hilsted, L., & Rehfeld, J. F. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.4.549 · Cited by 33
Jilesen, A. P. J., Busch, O. R. C., van Gulik, T. M., Gouma, D. J., & Nieveen van Dijkum, E. J. M. (2014) · Digestive Surgery · doi:10.1159/000370007 · Cited by 26
(2012) · Europe PMC (PubMed Central) · Cited by 10
Metadata
- Authors
- Stridsberg, M., Öberg, K., Li, Q., Engström, U., & Lundqvist, G.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 1995-01
- Volume
- 144
- Issue
- 1
- Pages
- 49-59
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2063506925
- Cited by
- 278
- References
- 0
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.